arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Opus Genetics, Inc.

IRD
$4.82 ▼ -0.32 (-6.23%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
25 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
40
Health
Weak
Moderately Bearish
auto_awesome

Analytical Summary

Opus Genetics, Inc. faces fundamental challenges. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $299.9M
Dividend Yield —
Revenue Growth 29.1% ↗
Op. Margin -271.9%
ROIC -234.3% ↗
FCF / Share $-0.57 ↗
Trailing P/E —
Price / Book 22.0x
FCF Yield —
Debt / Equity 0.07
info Valuation on last close. End-of-day price, Sep 23, 2026.

25-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$14.20M
↑ +29.1% —
Net Income Profit after all expenses
$-49.59M
↑ +13.8% —
Operating Margin Operating profit as % of sales
-271.9%
↓ -390.3% 0th
FCF / Share Free cash flow per share
$-0.57
↑ +40.8% —
Long-Term Debt Long-term obligations
$1.13M
— —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
1
Financial Health
85
Cash Quality ↑
49

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 25 years · 76 quarters